PREFERRED VENDOR

BUYER'S GUIDE

Business Solutions Pharmacy Services Pharmacy Supplies Retail Merchandise Retail Services



28202 Cabot Road, Suite 300 • Laguna Niguel, CA 92677 (949) 495–5257 • www.fpn.org



Now's the time to partner with VaxServe

We're a top specialty distributor owned by Sanofi, a global vaccine leader. We've partnered with pharmacies for more than two decades to help keep communities healthy through vaccination.

Together, we'll help grow your immunization programs through education, data-driven business insights, and innovative solutions.

Your one-stop source for vaccines

As a partner, you'll have access to:



Group purchasing organization (GPO) pricing



Streamlined ordering platforms



An extensive, expanding vaccine portfolio, including flu vaccines



Shipping visibility



Access to numerous manufacturers



Marketing support and vaccine expertise

Let's work together.





VAX8795

HASSLE FREE RX RETURNS





SIMPLIFIED REIMBURSEMENT

Receive credit from Return Solutions in a single check.



FASTER CREDIT

Your check is issued within as few as 10 days.



NO HIDDEN CHARGES

The fee is an all-inclusive percentage of your credit.

RETURN SOLUTIONS OFFERS THE FASTEST CREDIT IN THE INDUSTRY.

Receive a single check, for all pharmaceutical returns credit due through the OneCheck Select program, in your choice of 10, 30, 60, or 90 days after your return.



TRUSTED BY PHARMACY OWNERS SINCE 1992.

Spend more time on what matters most - your patients and your business.

LEARN MORE AT **DRUGRETURNS.COM**

Sign up today to receive the credit from your first return in just 30 days at no additional charge!

1.800.579.4804 drugreturns.com






Adjuvanted to help prevent seasonal influenza in adults 65+1



Designed to strengthen, broaden, and lengthen the duration of the immune response²⁻⁴

Learn more at fluad.com

For more information, please see Important Safety Information below and the Brief Summary on adjacent page.



INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUAD® QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

Do not administer FLUAD QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common (≥10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUAD QUADRIVALENT.

FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

REFERENCES: 1. FLUAD QUADRIVALENT. Package insert. Seqirus Inc; 2021. 2. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341-4348. doi:10.1016/j.vaccine.2011.09.061 3. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Del Giudice G. The history of MF59* adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013;12(1):13-30. doi:10.1586/erv.12.140 4. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses. 2008;2(6):243-249. doi:10.1111/j.1750-2659.2008.00059.x

FLUAD QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2022 Seqirus USA Inc. January 2022 USA-aQIV-21-0065



FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) Injectable Emulsion for Intramuscular Use 2021-2022 Formula

BRIEF SUMMARY OF PRESCRIBING INFORMATION

Consult the full US Prescribing Information for complete product information.

INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For intramuscular injection only.

CONTRAINDICATIONS

Do not administer FLUAD QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS

Guillain-Barré Syndrome: If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks. The 1976 swine influenza vaccine was associated with an elevated risk of GBS. [see Reference (1)] Evidence for a causal relationship of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons vaccinated.

Preventing and Managing Allergic Reactions: Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Altered Immunocompetence: The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Syncope: Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

Limitations of Vaccine Effectiveness: Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common (\geq 10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect rates observed in clinical practice.

The safety of FLUAD QUADRIVALENT was evaluated in two clinical studies in 4269 elderly subjects 65 years of age and older. Study 1 (NCT02587221) was a multi-center, randomized, observer-blind, non-influenza comparator-controlled efficacy and safety study conducted in 12 countries during the 2016-2017 Northern Hemisphere and 2017 Southern Hemisphere seasons. In this study, 3381 subjects received FLUAD QUADRIVALENT and 3380 subjects received a US-licensed non-influenza comparator vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Boostrix® [GlaxoSmithKline Biologicals]).

The mean age of subjects at enrollment was 72 years, 62% were female, 48% White, 34% Asian, 16% Other, 2% American Indian/Alaska Native, and 18% of Hispanic/Latino ethnicity.

Solicited local and systemic adverse reactions were collected for 7 days after vaccination in a subset of 665 subjects who received FLUAD QUADRIVALENT and 667 subjects who received the comparator vaccine. The percentages of subjects reporting solicited local adverse reactions are presented in Table 1a and systemic adverse reactions are presented in Table 1b. Onset usually occurred within the first 2 days after vaccination. The majority of solicited reactions resolved within 3 days.

Table 1a. Percentages of Subjects Reporting Solicited Local Adverse Reactions^a in the Solicited Safety Population^b within 7 Days of Vaccination (Study 1)

Local (Injection site) Reactions ^c	FLUAD QUADRIVALENT N=595-659	Non-Influenza Comparator Vaccine N=607-664
Injection site pain	16.3	11.2
Erythema ≥25mm	3.8	1.8
Induration ≥25mm	4.0	2.6
Ecchymosis ≥25mm	0.5	0.7

Study 1: NCT02587221

Abbreviation: N=number of subjects with solicited safety data

Non-Influenza Comparator Vaccine = combined Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Boostrix[®] (GlaxoSmithKline Biologicals)

^a All solicited local adverse events reported within 7 days of vaccination are included

Solicited Safety Population: all subjects in the exposed population who received a study vaccine and provided post-vaccination solicited safety data

Severe reactions of each type were reported in 1.1% or fewer subjects receiving FLUAD QUADRIVALENT; severe reactions of each type were also reported in the comparating group at similar percentages. Severe definitions: Erythema, Induration and Ecchymosis = >100 mm diameter, Injection site pain = prevents daily activity.

Table 1b. Percentages of Subjects Reporting Solicited Systemic Adverse Reactions^a in the Solicited Safety Population^b within 7 Days of Vaccination (Study 1)

Systemic Reactions ^c	FLUAD QUADRIVALENT N=595-659	Non-Influenza Comparator Vaccine N=607-664
Headache	10.8	8.3
Fatigue	10.5	8.8
Myalgia	7.7	6.1
Arthralgia	7.3	6.6
Chills	5.0	3.9
Diarrhea	4.1	3.0
Nausea	3.8	2.3
Loss of appetite	3.6	3.6
Fever ≥100.4°F (38°C)	1.7	1.2
Vomiting	0.8	1.1

Study 1: NCT02587221

Abbreviation: N=number of subjects with solicited safety data

Non-Influenza Comparator Vaccine = combined Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Boostrix® (GlaxoSmithKline Biologicals)

*All solicited systemic adverse events reported within 7 days of vaccination are included
*Solicited Safety Population: all subjects in the exposed population who received a study vaccine and provided post-vaccination solicited safety data

°Severe reactions of each type were reported in 1.1% or fewer subjects receiving FLUAD QUADRIVALENT; severe reactions of each type were also reported in the comparator group at similar percentages. Severe definitions: Nausea, Fatigue, Myalgia, Arthralgia, Headache, and Chills = prevents daily activity; Loss of appetite = not eating at all; Vomiting = 6 or more times in 24 hours or requires intravenous hydration; Form = ≥102.2°F (39°C).

Unsolicited adverse events (AEs) were collected for all subjects for 21 days after vaccination. Related unsolicited AEs were reported by 303 (9.0%) and by 261 (7.7%) of the subjects for FLUAD QUADRIVALENT, and Boostrix, respectively. For FLUAD QUADRIVALENT, injection site pain and influenza-like illness were the only unsolicited adverse reactions reported in \geq 1% of subjects (1.7% and 1.5%, respectively).

Serious adverse events (SAEs) and potentially immune-mediated adverse events of special interest (AESIs) were collected up to 366 days after vaccination. SAEs were reported by 238 (7.0%) FLUAD QUADRIVALENT recipients and 234 (6.9%) comparator recipients. There were no SAEs, AESIs or deaths in this study that were related to FLUAD QUADRIVALENT.

Study 2 (NCT03314662) was a multicenter, randomized, double-blind, comparator-controlled study conducted during the 2017-18 Northern Hemisphere influenza season. In this study, 888 subjects received FLUAD QUADRIVALENT, 444 subjects received the licensed adjuvanted trivalent vaccine (aTIV-1 - FLUAD® (trivalent formulation)) and 444 subjects received an adjuvanted trivalent influenza vaccine with an alternate B strain (aTIV-2).

The mean age of subjects at enrollment who received FLUAD QUADRIVALENT was 72.5 years. Female subjects represented 56.6% of the study population and the racial distribution of subjects was 91.6% Caucasian, 7.0% Black or African American, and ≤ 1% each for Asian, Native Hawaiian or Pacific Islander. American Indian or Alaska Native or Other.

Solicited local and systemic adverse reactions reported within 7 days after vaccination were similar to those reported for Study 1. Unsolicited AEs were collected for 21 days after vaccination. Related unsolicited AEs were reported by 39 (4.4%) and by 17-19 (3.8%-4.3%) of subjects administered FLUAD QUADRIVALENT or aTIV, respectively. For FLUAD QUADRIVALENT, injection site bruising (1.0%) was the only unsolicited adverse reaction reported in ≥ 1% of subjects.

Serious AEs and AESIs were collected up to 181 days after vaccination. Within 6 months after vaccination, 37 (4.2%) FLUAD QUADRIVALENT recipients and 18-28 (4.1%-6.3%) aTIV recipients experienced an SAE. There were no SAEs, AESIs or deaths in this study that were related to the study vaccine. There were no AEs leading to withdrawal from the study.

Postmarketing Experience: There are no postmarketing data available for FLUAD QUADRIVALENT. However, the postmarketing experience with FLUAD (trivalent formulation) is relevant to FLUAD QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions.

Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

Blood and lymphatic system disorders: Thrombocytopenia (some cases were severe with platelet counts less than 5,000 per mm³), lymphadenopathy

General disorders and administration site conditions: Extensive swelling of injected limb lasting more than one week, injection site cellulitis-like reactions (some cases of swelling, pain, and redness extending more than 10 cm and lasting more than 1 week)

Immune system disorders: Allergic reactions including anaphylactic shock, anaphylaxis, and angioedema



Musculoskeletal and connective tissue disorders: Muscular weakness

Nervous systems disorders: Encephalomyelitis, Guillain-Barré Syndrome, convulsions, neuritis. neuralgia, parasthesia, syncope, presyncope

Skin and subcutaneous tissue disorders: Generalized skin reactions including erythema multiforme, urticaria, pruritus or nonspecific rash

Vascular disorders: Vasculitis, renal vasculitis

DRUG INTERACTIONS

Concomitant Use With Other Vaccines: No clinical data on concomitant administration of FLUAD QUADRIVALENT with other vaccines is available.

If FLUAD QUADRIVALENT is given at the same time as other injectable vaccine(s), the vaccine(s) should be administered at different injection sites.

Do not mix FLUAD QUADRIVALENT with any other vaccine in the same syringe.

Concurrent Use With Immunosuppressive Therapies: Immunosuppressive or corticosteroid the rapies may reduce the immune response to FLUAD QUADRIVALENT.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

FLUAD QUADRIVALENT is not approved for use in persons < 65 years of age. There are insufficient human data to establish whether there is a vaccine-associated risk with use of FLUAD QUADRIVALENT in pregnancy.

There were no developmental toxicity studies of FLUAD QUADRIVALENT performed in animals. A developmental toxicity study has been performed in female rabbits administered FLUAD (trivalent formulation) prior to mating and during gestation. A 0.5 mL dose was injected on each occasion (a single human dose is 0.5 mL).

Lactation

Risk Summary

FLUAD QUADRIVALENT is not approved for use in persons < 65 years of age. No human or animal data are available to assess the effects of FLUAD QUADRIVALENT on the breastfed infant or on milk production/excretion.

Pediatric Use

Safety and effectiveness of FLUAD and FLUAD QUADRIVALENT (same manufacturing process and overlapping composition with FLUAD) were evaluated in clinical trials conducted in children 6 months to <72 months of age. Data from these trials are inconclusive to demonstrate the safety and effectiveness of FLUAD QUADRIVALENT in children 6 months to <72 months of age. The safety and effectiveness of FLUAD QUADRIVALENT in infants less than 6 months of age and in children older than 72 months of age have not been evaluated.

Geriatric Use

Safety and immunogenicity of FLUAD QUADRIVALENT have been evaluated in adults 65 years of age and older.

REFERENCE

1. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339(25):1797-1802.

To report SUSPECTED ADVERSE REACTIONS, contact Segirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.




FLUAD QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates. Segirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA US License No. 2049

©2021 Segirus USA Inc. December 2021 USA-aQIV-21-0073



Streamline Your Purchasing Process

Save Time and Money with a Single Supply and Equipment Vendor



InSource is your go-to source for clinical supplies, equipment, pharmaceuticals, and more.

Between stocking your store or warehouse, maintaining your equipment, and sanitizing your space, it takes time and labor to keep your business running smoothly. Simplify the process by partnering with one vendor for all of your purchasing needs.

CONVENIENCE



Streamline logistics and fulfillment with a single medical supply partner

VALUE



Benefit from cooperative purchasing and long-term supplier relationships

EXPERTISE



Access over 30 years of health care supply chain experience

1-800-366-3829 • www.insourceonline.com customersfirst@insourceonlin.com

23IN1253







DSCSA 360

This program includes all of the below features and tools to ensure your DSCSA Compliance:

Easy to follow <i>Compliance Guide</i> to walk you through the implementation process.	Provides alerts to you when there is suspect data in your transaction information.
Required Policies and Procedures/SOPs.	Provides alerts to you when recall information matches products you have received.
Required forms.	Provides alerts to you when your authorized partner licenses and credentials are expiring.
Support from Compliance experts to help you every step of the process.	DSCSA Audit assistance is available at no cost.
Works with authorized trading partners to begin collecting your electronic transaction data (EPCIS) automatically.	Provides Employee Training on the Software and SOPs.
Provides all of the electronic transaction data from all your authorized trading partners on easy-to-use website.	Training and education on identifying suspect products.
Assistance with obtaining Global Location Numbers (GLN).	Scanning of incoming products.



Sign-up now and get a month FREE!

With more than 24,000 designs, **Designer Greetings** offers the **PERFECT CHOICE** for every occasion.



PROMOTION: \$1,000 RETAIL VALUE CARDS FOR \$250 COST

- DON'T MISS OUT ON THIS GREAT OFFER!
- MAKE A 75% MARGIN
- AVAILABLE IN EVERYDAY ASSORTMENTS:

Assortment # 1: General & Age Birthday

Assortment # 2: Family Birthday Titles

Assortment # 3: Wedding/Anniversary/Baby/Get Well/Thank You/Sympathy

Seasonal Assortments Available





SWITCH YOUR GREETING CARD DEPARTMENT TODAY!

800.654.6960 | www.designergreetings.com | @DesignerGreetings





FRANKLIN **EYEWEAR®**

SUN & READING GLASSES

\$9.99 RETAIL / \$4.50 COST

EACH DEAL PRICE \$648 144 PAIR @ \$4.50 A PAIR

SUNGLASSES PRICE TAGS COLOR CODED BY CATEGORY

READING GLASSES PRICE TAGS COLOR CODED BY STRENGTH

> EASY MERCHANDISING & RE-ORDERING

GREAT VARIETY OF QUALITY STYLES

FREE DISPLAY | FREE SHIPPING





Associated with most buying groups ... probably yours too!

CALL AL (877) 766-0321 OR VISIT WWW.FRANKLINEYEWEAR.COM

MyFluVaccine[®]

Helping You Be a

#FluFighter

With MyFluVaccine® you can take control and manage your flu inventory with ease while meeting your flu clinic demands. Our revolutionary online vaccine ordering platform paves the way to help you improve your patients' care.



CHOICE

Multiple presentations from top manufacturers.

CONFIDENCE

Dependable deliveries to meet your patients' needs.

COMMITMENT

Aligned with manufacturers' estimated shipping commitments.

SAFETY

Guaranteed Channel Integrity® ensures safe, reliable products for your patients.

Free Next Business Day shipping for orders placed by 12:00 p.m. PT.

MyFluVaccine® (MFV) is a program of FFF Enterprises Inc., the nation's largest and most trusted specialty pharmaceutical distributor and diversified healthcare organization.

YOU PICK THE PRODUCTS • YOU PICK THE QUANTITY • WE DELIVER

MyFluVaccine.com | FFFenterprises.com | (800) 843-7477 | Fax (800) 418-4333 ©2023 FFF Enterprises Inc. All Rights Reserved. FL1179-JB Rev 060523





Take advantage of group buying power with Staples®.

As a member of your buying organization, you get exclusive pricing on all the right tech for your pharmacy. So you can spend your money on keeping employees productive — not on maintaining outdated equipment. Give your pharmacy and your budget the tech advantage today.

Products include:

- Mice and keyboards
- Tablets and laptops
- Monitors, webcams and headsets
- Digital cameras and memory cards
- Printers and shredders
- Privacy screens and laptop locks
- Storage devices
- Secure hardware recycling

Order these items on StaplesAdvantage.com.

Don't have an account? Set up your account today!



Please note that this discount program is only valid on StaplesAdvantage.com, not Staples.com or in Staples stores.







CONNECTING PATIENTS TO COMMUNITY PHARMACIES



SHOP OTC AND POC TESTING SUPPLIES

We hand selected the industry's best OTC and POC test kits for your independent pharmacy including:

Strep **♣** A1C

♣ HIV Mono

♣ RSV and more!




CLIA WAIVER APPLICATION SUPPORT

Having a CLIA waiver opens a world of opportunity for your pharmacy. For just \$59, we'll take care of your CLIA waiver paperwork and follow up, so you can continue focusing on serving your patients!



QUICK AND ACCURATE RESULT REPORTS

Ready to save time and money? Our simple reporting software allows your patients to schedule and pay for their test, plus quickly receive results- all from their mobile device.



Your cost to set up, implement, and maintain: \$0

Ready to get started? Contact us at info@sitelabsglobal.com or call 828.616.5400



01

Rx RETURNS

Maximize credit recovery by leveraging Inmar's Returns Management Solution. Onsite and offsite service options combined with RxReturns Intel™ dashboards ensure robust reporting, enhanced visibility and manufacturer policy compliance.

04

USP <800> SOLUTIONS

Subscription-based service providing an annual Assessment of Risk for handling hazardous drugs to protect your staff and patients.

02

CONSUMER DRUG TAKE-BACK

This customer-friendly, secure medication take-back program generates publicity, community goodwill and store traffic while supporting efforts to combat prescription drug abuse and helping to protect the environment from the effects of improper drug disposal.

03

DSCSA PHARMACY COMPLIANCE

RxTransparent, a cloudbased subscription service that streamlines DSCSA medication track and trace requirements, enabling transparency and regulatory compliance for your pharmacy.

05

Rx RECON AND COLLECTIONS

Inmar's Rx Recon and Collections Services mitigate receivables risk, improve cash flow and deliver critical business-building intelligence.

inmar.com | solutions@inmar.com | (866) 440-6917







Valuations

Feasibility Studies

Complete Startup Services

Acquisition & Transfer Consulting

Regulatory Compliance
Programs



Pharmacy test-to-treat SETVICES (The future of testing: protocol automation)



Opportunity to streamline test-to-treat programs

- Today, patients must fill out lengthy screening questionnaires
- Pharmacists are required to follow healthcare algorithms which can be complex
- Based on the test, results may need to be reported to regulatory agency



Together, QuidelOrtho and Workflow Services by ImageMover provides a solution that supports and simplifies the test-to-treat process by creating a turn-key solution for the pharmacist. Now, patient intake is automated, result management is integrated through the Sofia® 2 point-of-care testing solution with outputs being directly reported to regulatory agency as required. All with one simple system.

This partnership combines Sofia 2 with Workflow Services, creating a simplified solution for intake/ reporting and a state-of-the-art, point-of-care testing solution.

> With Workflow Services, pharmacies can onboard patients 80% faster than with the current manual process.

> > Workflow Services:



Provides HIPAA compliant communication with the patient

Automatically reports to the health authorities



Provides secure record-keeping for audits

quidelortho.com | 800-874-1517 | customerservice@quidel.com workflowservices.com | 608-620-4980 | info@imagemovermd.com





FL20299100EN00 (02/23)





Workflow Services paired with Sofia 2 automates the required healthcare protocols for the pharmacist from patient intake to results driving operational efficiencies. Sofia 2, is an automated small bench top system used by over 85,000 hospitals, urgent cares, physician offices, and pharmacies globally.

Sofia 2 provides:

- **Excellent sensitivity and specificity** compared to molecular and viral culture methods
- Fluorescent technology guarantees an objective result with no potential for subjective interpretation
- **Dual modes** from walkaway to batch testing, allowing you to run a single sample or multiple samples at a time, up to 30 tests per hour
- **Results in 3-15 minutes** (differs by assay)

- Unprecedented test menu available: Influenza A+B, Strep A, SARS, Flu+SARS, RSV, Lyme disease, Campylobacter
- **Small instrument size** and room-temp storage of kits are suitable for all pharmacies
- **Integrated data management** with connectivity to Workflow Services by ImageMover as well as a secure, remote instrument management system, Virena®
- Future Growth: QuidelOrtho's Point-of-Care platform scalable for future innovation

The process is simple:

Patient completes short questionnaire and self-registers (no app download required)

Pharmacist reviews patient information, consults with patient, and performs testing Workflow Services automatically reports results and pharmacist dispenses medication

A variety of services with QuidelOrtho's comprehensive menu of tests

- Works with any Sofia 2 test, which automates testing providing an objective result no interpretation required
- Digital decision support defines coding for reimbursement
- Mobile app, web interfaces, and real-time analytics enhance operational efficiency and organizational capability

Optimize the time it takes to deliver POC services

- Allows patients to securely complete forms from their own device
- Reduces manual input for pharmacists by implementing digital workflows
- Implements flexible workflows on Sofia 2, allowing pharmacists to focus on patient care, not the test, by minimizing hands-on-time

Simplified, secure automatic communication

- Sofia 2 drives efficiency by automatically sending results to Workflow Services, which allows for easy communication of outcomes to patients
- Digitized data can integrate with other pharmacy systems and provide insights driving improved care
- Satisfies the regulatory reporting requirements for test results by automating the process

quidelortho.com | 800-874-1517 | customerservice@quidel.com workflowservices.com | 608-620-4980 | info@imagemovermd.com





FL20299100EN00 (02/23)





PPRB.COM

sales@pprb.com 1.877.544.4575 @pprbconnect

Consistent tangible marketing is important.

With PPRB's signature line of printed wall and desk calendars as well as additional print products, like coloring books, pocket planners, and magnets, staying connected with your current & future customers is easy.





Helping pharmacies build relationships, generate sales, and win loyal customers across North America.

Your store's information will be prominently displayed on the generous bottom flap imprint area of PPRB's wall calendars.

Include vour business contact info such as your store address, phone and fax numbers, store hours and website links so vour customers can connect with you in-store and on your digital platforms too.





KNOWLEDGEABLE & DEPENDABLE

Remind your customers that you are available to support their well-being by providing the best health care advice and products available to them.



VALUABLE CONTENT


Customers will refer to your calendars for recipes, health tips, day-to-day planning, organizing, and more. Each view/impression encourages them to return to your store for health and wellness inquiries and products.



STAY RELEVENT & BUILD TRUST

Foster long-term connections with current and prospective customers in your community.

D**U**LLAR**DAYS.COM**



Member Benefits

- Free shipping on orders of \$399 or more
- 30k+ products in stock & ready to ship today
- Products are sold by the case

- 50%-80% profit margins
- Retail-ready displays & plan-o-grams
- Unparalleled customer care

3 Easy Ways to Shop!

877.837.9569 | sales@dollardays.com | www.dollardays.com



Diversify Revenue Beyond Dispensing

LEARN HOW



Healthy patients. Healthier bottom line.

Picking up? While you're here, I can also... Review medicare plans Give flu vaccine Do a CMR



BUSINESS INSURANCE PROGRAM

FOR INDEPENDENT PHARMACIES

When it comes to insurance, having a choice is important. That is why Pharmacy Insurance Network (aka PIN) offers a competitive network of business insurance options.



PROGRAM FEATURES:

All lines of coverage are available, including: Pharmacy Professional Liability, General Liability, Property, Auto, Umbrella, Workers Compensation, Cyber Liability, etc.

ENDORSED VENDOR:

PIN is proud to be an endorsed vendor of:

- 1 National Independent Pharmacy Association
- 10 Regional Independent Pharmacy Associations

SAVE 21% ON AVERAGE WITH THE PHARMACY INSURANCE NETWORK

CONTACT US TODAY AND LET US HELP INSURE YOUR CONTINUED SUCCESS!



Office: 215-491-2704 www.selzercompany.com

Michael P. Egan, Jr., CIC PHARMACY PROGRAM DIRECTOR

The Selzer Company
Mike@SelzerCompany.com

Pharmacy Insurance Network Mission Statement

Insuring the continued success of the independent pharmacy industry by dispensing an exclusive network of specialized business insurance options to enhance the protection of and increase the profitability of independent pharmacy owners across the country.



MADE EASY



AquaSol Rx Liquid Structure™ CBD comes in an easy-to-take softgel that provides reliable, consistent dosing.



Your patients will experience superior absorption from patented technology that gets more CBD into the bloodstream than has ever been possible before.



CBD should only be available in a pharmacy like yours, NOT in convenience stores and gas stations.



High profit margin item sold only to independent retail pharmacies.







Scan the QR code!



866-478-1772 (ব্



AquaSolRx.com



Protect Your Assets

Safeguard Vaccines, Irreplaceable Samples, and Sensitive Environments with OneVue Sense®

- Automated Data Logging: Monitor temperatures from -328 °F to 302 °F (-200 °C to 150 °C)
- Real-Time Alerts: Receive call, text, and email alerts for out-of-range conditions
- Compliance Made Easy: Enjoy on-demand reporting and cloud-based data access



OneVue Sense Environmental Monitoring

The OneVue Sense suite also offers Indoor Air Quality, Water Leak, Differential Pressure, and Contact Closure Sensors to further help your pharmacy staff maintain a clean, safe, efficient, and compliant facility.



Humidity





Water Leak Pressure - (1) Contact Closure

Contact Primex today!

info@primexinc.com www.primexinc.com/onevue-sense 855-602-2934




© 2023 Primex Wireless, Inc. PRIMEX, PRIMEX WIRELESS, ONEVUE, and ONEVUE SENSE are trademarks and registered trademarks of Primex Wireless, Inc. All Rights Reserved.





PROVIDING CUSTOMIZED SOLUTIONS FOR INDEPENDENT PHARMACIES

HELP YOUR **CUSTOMERS** WHEN THEY NEED A DOCTOR, LAWYER, THERAPIST OR VETERINARIAN





KLEEN BILL CREATES A CUSTOMIZED VIRTUAL BENEFITS PLATFORM FOR YOUR PHARMACY WHILE ALSO PROVIDING THE CONSUMER ENGAGEMENT SUPPORT THAT TRANSLATES INTO LOYAL CUSTOMERS EXPERIENCING BETTER OUTCOMES.

TO LEARN MORE, CALL US TODAY AT 704.965.3607 OR VISIT OUR SITE AT

WWW.KLEENBILL.COM

Turn your group health plan problem into an opportunity.

Call us today to learn how.



3101 S Phillips Ave

| health@hahnfinancialgroup.com | 800-516-HAHN

Investment advisory services and insurance products offered through Hahn Financial Group, Inc., an SEC Registered Investment Advisor.





FUTURE OF PHARMACY, REVENUE GROWTH TODAY

Wherever your pharmacy is with clinical services, Workflow Services can help you commercialize new services, optimize existing workflows, and maximize revenue potential.

We will guide you to:

- Launch services allowed in your state
- Secure contracts with medical insurance companies
- Develop and deploy clinical protocols
- Get paid for services with cash or insurance



Evolve beyond a traditional retail setting. Scan the QR code to learn more.

HOW IT WORKS



1 - Connect with Patients



2 - Deliver Medical Services



3 - Streamline Payment and Reimbursement





WE WANT TO HELP.



WORKFLOW SERVICES PLATFORM

- User-Decision Support Software & Digital Protocols
- Patient Communication & Education Tools
- Payor Credentialing & Contracting for Pharmacists
- Patient Self-Pay & Co-Pay

- Universal Patient Health Record Access
- Building & Submitting Medical Claims
- Pharmacy Management
 System Integration

PARTNER SPOTLIGHT



QuidelOrtho and Workflow Services provide a solution that supports and simplifies the test-to-treat process by creating a turn-key solution for the pharmacist.









American Associated Pharmacies

Phoenix, AZ – Scottsboro, AL rxaap.com

American Pharmacies

Corpus Christi, TX

<u>aprx.org</u>

American Pharmacy Services Corp.

Frankfort, KY apscnet.com

Compliant Pharmacy Alliance

Stoughton, WI compliantrx.com

Epic Pharmacies

Mechanicsville, VA epicrx.com

Independent Pharmacy Alliance, Inc.

Cranbury, NJ ipagroup.org

Independent Pharmacy Cooperative

Sun Prairie, WI ipcrx.com

Keystone Pharmacy Purchasing Alliance

Philadelphia, PA kpparx.com

Northeast Pharmacy Service Corp.

Framingham, MA northeastpharmacy.com

PBA Health

Kansas City, MO pbahealth.com

Pharmacy Owners Alliance

Coral Springs, FL rxpoa.org

PPSC

Tallahassee, FL ppsconline.com

Quality Care Pharmacies

Macedon, NY qcpharmacies.com

RxPlus Pharmacies, Inc. Wheat

Ridge, CO rxplus.com

Sav-Mor Pharmacy Services

Southfield, MI mysavmorpharmacy.com

Smart-Fill Management Group

Austin, MN smart-fill.com

The Pharmacist Choice

Brentwood, TN thepharmacistchoice.com

WSPC

Lake Oswego, OR wspcrx.com

Preferred Vendors

Doing business with our preferred vendor partners strengthens the purchasing alliance of independent pharmacies and provides increased opportunities for future negotiations. Your participation leverages our collective buying power to offer the most competitive contracts.

Thank you for your continued commitment to independent pharmacy and for your patronage of our preferred vendor partners.

Advasur/DSCSA 360- advasur.com

American Greetings- americangreetings.com

Animal Med Express- animalmedexpress.com

AquaSol Rx- aquasolrx.com

Avis Car Rental- avis.com

Budget Car Rental- budget.com

Designer Greetings- <u>designergreetings.com</u>

DollarDays- dollardays.com

FFF Enterprises- fffenterprises.com

Fillmaster- fillmastersystems.com

First Financial Bank- ffb1.com

FLAVORx- flavorx.com

Franklin Eyewear- <u>franklineyewear.com</u>

Hahn Financial Group, Inc. - hahnfinancialgroup.com

Inmar Intelligence- inmar.com

InSource- insourceonline.com

Pharmacy Insurance Network- selzercompany.com

PPRB Marketing- pprb.com

PrescribeWellness- prescribewellness.com

Primex- primexinc.com

PRS Pharmacy Services- prsrx.com

Quidel- quidel.com

Return Solutions- drugreturns.com

Segirus- segirus.com

SiteLabs- sitelabsglobal.com

Staples Advantage- staplesadvantage.com

Take Charge- takechargerx.com

VaxServe- vaxserve.com

Workflow Services- workflowservices.com